Equity Profile

TVTX

TRAVERE THERAPEUTICS

Health CareBiotechnology$4.3B

May4Mon

Post-Earnings Recap

ReportedQ1-2026After Close4:01 PM EDT

Travere Therapeutics Beats on EPS, Stock Up 1.79%

Metric	Actual	Expected	Surprise
EPS	$0.05	$-0.05	+116.78%
Revenue	—	$136M	—

management commentary, guidance changes, and full analysis available with Pro.

Travere Therapeutics Beats on EPS, Stock Up 1.79%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.05	$-0.05	+116.78%
Revenue	—	$136M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Travere Therapeutics reported a surprising positive EPS, beating expectations significantly. However, there was no revenue reported against the consensus estimate. The stock reacted positively, rising by 1.79%, likely reflecting investor optimism about the unexpected earnings performance.

Company Snapshot

Travere Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

-$0.05

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$136M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Travere Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases. With a market cap of $4 billion, it plays a crucial role in addressing unmet medical needs in the health care sector.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.42%

Avg Stock Reaction

+0.68%

Last Quarter Recap

In Q4 2025, Travere reported an EPS of $0.37, significantly exceeding expectations. The stock reacted positively, gaining 5.13% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Travere's upcoming earnings, expecting a small loss in EPS but solid revenue figures.

Bull Case

If Travere can beat the EPS estimate and show strong revenue growth, it could signal a turnaround in profitability and boost investor confidence.

Bear Case

Conversely, if the company misses on both EPS and revenue, it may raise concerns about its financial health and future growth prospects.

Key Metrics to Watch

EPS

-$0.05

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$136M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the company achieve revenue of at least $136 million?

Meeting or exceeding this revenue target will indicate strong demand for Travere's products and could positively influence stock performance.

What is the outlook for EPS moving forward?

Guidance on future earnings will be critical for assessing the company's path to profitability and investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Travere's ability to leverage recent product developments, which could drive higher-than-expected revenue.

Supporting Evidence

The company's recent earnings surprises indicate a potential for continued strong performance.

Options pricing suggests a higher volatility expectation, which may reflect insider confidence in upcoming results.

Key Risk

If revenue exceeds $162 million, it could invalidate the cautious consensus and shift investor sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Travere's ability to balance growth with profitability, especially after recent strong earnings surprises.

Bull Confirmed If

An EPS of $0.10 or better would confirm the bull case, showcasing improved cost management and revenue generation.

Bear Confirmed If

An EPS loss greater than $0.23 would confirm the bear case, raising concerns about the company's financial stability.

Pre-Earnings Positioning

Options Market

Implied Move

±10.14%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±10.4% while TVTX has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

106.6%

Calls (49K)P/C Ratio: 1.62Puts (6K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$8.7M

211,102 sh

9 insiders

Net

$8.7M

Net selling

Most Active Insiders· 19 open-market trades

Chief Legal Officer and GCREED ELIZABETH E
$2.1M
Net selling

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

115.25%

of float

Insider

0.76%

of float

Holders

380

institutions

Top Holders· as of Dec 2025

Janus Henderson Group PLC
10,511,166 sh · $425.7M
11.38%
-0.8%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Travere beats expectations, history suggests a potential stock increase of around 0.52%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A significant miss could lead to a decline, with history suggesting an average drop of around 4.63%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected impact on revenue.
2Management's commentary on cost management strategies and their effect on EPS.
3Insights into market demand for Travere's therapies and any new partnerships.
4Guidance on future earnings and revenue expectations for the next quarter.
5Responses to analyst questions regarding competitive pressures in the biotechnology space.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Travere Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

-$0.05

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$136M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.42%

Avg Stock Reaction

+0.68%

Last Quarter Recap

In Q4 2025, Travere reported an EPS of $0.37, significantly exceeding expectations. The stock reacted positively, gaining 5.13% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Travere's upcoming earnings, expecting a small loss in EPS but solid revenue figures.

Bull Case

If Travere can beat the EPS estimate and show strong revenue growth, it could signal a turnaround in profitability and boost investor confidence.

Bear Case

Conversely, if the company misses on both EPS and revenue, it may raise concerns about its financial health and future growth prospects.

Key Metrics to Watch

EPS

-$0.05

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$136M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the company achieve revenue of at least $136 million?

Meeting or exceeding this revenue target will indicate strong demand for Travere's products and could positively influence stock performance.

What is the outlook for EPS moving forward?

Guidance on future earnings will be critical for assessing the company's path to profitability and investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Travere's ability to leverage recent product developments, which could drive higher-than-expected revenue.

Supporting Evidence

The company's recent earnings surprises indicate a potential for continued strong performance.

Options pricing suggests a higher volatility expectation, which may reflect insider confidence in upcoming results.

Key Risk

If revenue exceeds $162 million, it could invalidate the cautious consensus and shift investor sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Travere's ability to balance growth with profitability, especially after recent strong earnings surprises.

Bull Confirmed If

An EPS of $0.10 or better would confirm the bull case, showcasing improved cost management and revenue generation.

Bear Confirmed If

An EPS loss greater than $0.23 would confirm the bear case, raising concerns about the company's financial stability.

Pre-Earnings Positioning

Options Market

Implied Move

±10.14%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±10.4% while TVTX has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

106.6%

Calls (49K)P/C Ratio: 1.62Puts (6K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$8.7M

211,102 sh

9 insiders

Net

$8.7M

Net selling

Most Active Insiders· 19 open-market trades

Chief Legal Officer and GCREED ELIZABETH E
$2.1M
Net selling

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

115.25%

of float

Insider

0.76%

of float

Holders

380

institutions

Top Holders· as of Dec 2025

Janus Henderson Group PLC
10,511,166 sh · $425.7M
11.38%
-0.8%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Travere beats expectations, history suggests a potential stock increase of around 0.52%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A significant miss could lead to a decline, with history suggesting an average drop of around 4.63%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected impact on revenue.
2Management's commentary on cost management strategies and their effect on EPS.
3Insights into market demand for Travere's therapies and any new partnerships.
4Guidance on future earnings and revenue expectations for the next quarter.
5Responses to analyst questions regarding competitive pressures in the biotechnology space.